Abstract
Background The epidemiology of prenatal cannabis use in Canada following legalization remains unknown despite increasing evidence for associated health risks. Our study aimed to identify current risk factors for, and patterns of, prenatal cannabis use and second-hand cannabis exposure in Alberta.
Methods We conducted a secondary analysis of prospective data from a 2019 study in Calgary AB, of 153 pregnant (<28 weeks gestation at enrollment), English-speaking Alberta residents. We conducted descriptive analyses of prenatal cannabis use patterns (timing, frequency, dose, modes and reasons for use) and logistic regression to identify risk factors for direct use and second-hand exposure.
Results Odds of prenatal cannabis use were significantly higher among those who did not own their home (Odds Ratio (OR) 3.1; 95% CI:1.6-9.6), smoked tobacco prenatally (OR 3.3,95% CI:1.2-9.3) and used illicit substances in the past (OR 3.2; 95% CI:1.7-9.9), and lower for those consuming alcohol prenatally (OR 0.3, 0.12-0.89). Among the 90 (58%) participants who used cannabis prenatally, the majority used for medicinal reasons (96%), at least daily (67%), by smoking (88%), in all trimesters of pregnancy (66%). Although reported dose-per-use was commonly low, cumulative doses over pregnancy were high.
Interpretation Our study finds marked differences in prenatal cannabis use risk factors, and patterns of more frequent use sustained throughout pregnancy with perceived medicinal indications than pre-legalization studies. Prenatal care providers should include cannabis explicitly in medication counselling. Further prospective studies are needed as the impacts of prenatal cannabis on maternal and infant health in Canada may currently be underestimated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded by a research grant from the Alberta Childrens Hospital Research Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Calgary Conjoint Health Research Ethics Board approved this Study (Ethics ID: REB19-0670).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* denotes shared first-authorship
Funding: This project was funded by a research grant from the Alberta Children’s Hospital Research Institute.
Author conflict statements: No Authors have any conflicts of interest to declare.
Data Availability
The datasets generated and analysed during the current study are not publicly available due to privacy restrictions outlined in the ethics agreement. De-identified may be made available from the corresponding author on reasonable request following publication.
